Maplight Therapeutics Inc (MPLT)

Jun 11, 2026

MapLight Therapeutics (MPLT) Surges 3.31% as Positive Momentum BuildsHull Moving Average - newsline.com

Jun 11, 2026

Jun 11, 2026

MPLT Q1 2026 Earnings: EPS Misses Estimates by 20% as Pre-Revenue Biotech Continues Clinical Progress - newsline.com

Jun 11, 2026

Jun 07, 2026

MapLight Therapeutics (MPLT) Drops Over 6% as Key Support Level NearsVWAP Breakout - newsline.com

Jun 07, 2026

Jun 03, 2026

What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com

Jun 03, 2026

Jun 02, 2026

MPLT Maintained by Stifel -- Price Target Raised to $36.00 - GuruFocus

Jun 02, 2026

Jun 02, 2026

Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $36 - Moomoo

Jun 02, 2026

Jun 01, 2026

Stifel raises MapLight Therapeutics price target on drug potential By Investing.com - Investing.com Canada

Jun 01, 2026

Jun 01, 2026

MPLT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com

Jun 01, 2026

May 31, 2026

MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - AOL.com

May 31, 2026

May 30, 2026

MPLT Options Volatility — NASDAQ:MPLT - TradingView

May 30, 2026

May 30, 2026

MPLT Options Chain — NASDAQ:MPLT - TradingView

May 30, 2026

May 28, 2026

MapLight Stock Slips Ahead of August Drug Update - Bez Kabli

May 28, 2026

May 28, 2026

MPLT Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Development SpendingEarnings Call Q&A - The Legal Advocate

May 28, 2026

May 28, 2026

MPLT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus

May 28, 2026

May 27, 2026

MPLT Initiated Coverage by UBS -- Rating Set to Buy, Target at $48 - GuruFocus

May 27, 2026

May 26, 2026

MapLight Therapeutics Rises 2.4%, Nearing Key Resistance Level (MPLT)Resistance Breakout Stocks - The Legal Advocate

May 26, 2026

May 25, 2026

MapLight Therapeutics (MPLT) Tests Key Support After 1.8% DeclineSeasonality Effect - The Legal Advocate

May 25, 2026

May 22, 2026

Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus

May 22, 2026

May 21, 2026

MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus

May 21, 2026

May 21, 2026

MapLight Therapeutics (MPLT) Q1 2026 Stumbles — EPS $-1.34 Misses TargetPro Trader Picks - Newser

May 21, 2026

May 21, 2026

Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada

May 21, 2026

May 21, 2026

MapLight Therapeutics Q1 2026 Earnings: Wider Loss than Anticipated, Yet Shares Climb on Pipeline OptimismRevenue Surprise History - The Legal Advocate

May 21, 2026

May 20, 2026

Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside - TipRanks

May 20, 2026

May 19, 2026

MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN

May 19, 2026

May 19, 2026

MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria

May 19, 2026

May 19, 2026

MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo

May 19, 2026

May 18, 2026

MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com

May 18, 2026

May 18, 2026

MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan

May 18, 2026

May 17, 2026

MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal

May 17, 2026

May 15, 2026

MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool

May 15, 2026

May 15, 2026

Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks

May 15, 2026

May 15, 2026

T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan

May 15, 2026

May 15, 2026

A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo

May 15, 2026

May 15, 2026

MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

May 15, 2026

May 15, 2026

MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView

May 15, 2026

May 14, 2026

MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus

May 14, 2026

May 14, 2026

MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks

May 14, 2026

May 14, 2026

MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo

May 14, 2026

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 14, 2026

[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 14, 2026

May 14, 2026

MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan

May 14, 2026

May 14, 2026

What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan

May 14, 2026

May 14, 2026

MapLight Therapeutics (MPLT) Q4 2025 Earnings: Miss Sparks ConcernNet Profit Margin - newsline.com

May 14, 2026